Strategic Intelligence That Compounds Over Time.
Transforming Market Access from a "Final Hurdle" into a "Foundational Strategy."
The Billion-Dollar Disconnect
Too often, market access is treated as a downstream task—something to "fix" after the clinical data is locked. This disconnect creates billion-dollar value leaks: Phase III trials that miss HTA requirements, evidence gaps that trigger price cuts, and launch delays caused by avoidable objections.
Continuous Predictive Foresight
We provide a continuous thread of strategic intelligence that starts years before launch, ensuring that every development decision builds toward a commercially successful asset. Clinical strategy and market reality, unified from day one.
The Lifecycle Advantage
Early Strategy
Capital Efficiency & Early De-Risking
Clinical Dev
Protocol Stress-Test & Dual Design
Pre-Launch
Submission Risk Radar & Optimization
Launch
Value Defense & Revenue Maximization
Early Strategy (Pre-Clinical / Phase I)
Capital Efficiency & Early De-Risking
Before you commit massive resources to a pivotal program, you need to know if the asset has a viable path to reimbursement.
Comparator Landscape Scan
Identify the standard of care evolution to predict the correct comparator 5 years in advance.
Protocol Concept Review
Filter out trial designs that satisfy regulators but fail the "payer test."
Clinical Development (Phase II/III)
Asset Protection & Dual-Purpose Design
The most expensive mistake in pharma is running a flawless Phase III trial against the wrong comparator. We embed payer logic into the design phase.
HTA-Ready Trial Design
Ensure endpoints and patient subpopulations align with G-BA/HAS requirements, not just EMA/FDA.
Comparator Selection
Validate your control arm against the predicted future standard of care.
Pre-Launch (Dossier Prep)
Launch Excellence & Speed
Don't wait for the HTA body to find the flaws in your dossier. We help you find them first.
Objection Anticipation
Predict the top 3-5 objections the HTA committee will raise and prepare robust counter-evidence.
Scenario Analysis
Model different submission strategies (e.g., broad vs. narrow label) to maximize the probability of a high "Added Benefit" rating.
Launch (Market Access)
Revenue Maximization
When you enter price negotiations, data is your only leverage. We arm you with the numbers to defend your value.
Pricing Corridor Modeling
Establish a realistic, data-backed negotiation range based on analog assessments.
Negotiation Support
Simulate payer counter-arguments and equip your team with evidence-based rebuttals.
The Bottom Line
End-to-End Alignment.
By engaging gaide across the lifecycle, you don't just get a report; you get a strategic partner that evolves with your asset. We turn the fragmented process of drug development into a cohesive journey toward commercial certainty.
View Our Solutions